Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | PAK4 | O96013 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | LTK | P29376 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702750 | 0.79 | PAK4 (0.38) | GSK3BPIK3C3AURKADAPK3JAK2 | |
| SCHEMBL14026511 | 0.79 | PAK4 (0.38) | GSK3BPIK3C3AURKADAPK3JAK2 | |
| SCHEMBL91111 | 0.77 | GSK3B (0.35) | GSK3BPIK3C3AURKADAPK3JAK2 | |
| SCHEMBL61333 | 0.74 | KMT2A (0.53) | AURKAAURKBPOLBGAASMN1; SMN2 | |
| SCHEMBL63682 | 0.72 | AURKA (0.46) | GSK3BPIK3C3AURKADAPK3JAK2 | |
| SCHEMBL32683559 | 0.71 | LMNA (0.40) | SMN1; SMN2 | |
| SCHEMBL786647 | 0.71 | LMNA (0.55) | GSK3BAURKAABL1LCKFYN | |
| SCHEMBL19796066 | 0.71 | MAPT (0.41) | PAK4IGF1RMAPTPOLBSMN1; SMN2 | |
| SCHEMBL1123924 | 0.71 | — | — | |
| SCHEMBL6661092 | 0.69 | CDK2 (0.46) | JAK2PAK4CSF1RJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954277-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-1948193-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120142660-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-07 | — | — | US | disclosed |
| US-8129399-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7767672-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090181938-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-16 | — | — | US | disclosed |
| US-7528142-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1948193-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070249031-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007056164-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | ABL1, PRKDC, MAP3K5 | GSK3B 374/4885PIK3C3 91/4885AURKA 66/4885 |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, PRKDC, MAP3K5 | GSK3B 374/4885PIK3C3 91/4885AURKA 66/4885 |
| US-20120142660-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | ABL1, PRKDC, MAP3K5 | GSK3B 374/4885PIK3C3 91/4885AURKA 66/4885 |
| US-20090181938-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | ABL1, PRKDC, MAP3K5 | GSK3B 374/4885PIK3C3 91/4885AURKA 66/4885 |
| US-20070249031-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, PRKDC, MAP3K5 | GSK3B 374/4885PIK3C3 91/4885AURKA 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.